Bitrobius Secures £700k to Deliver Genes into Mitochondria

Bitrobius Genetics has received a £700,000 grant from the Advanced Research and Invention Agency (ARIA) to explore a new frontier in gene therapy. The funding supports a project to determine whether the company’s existing gene-delivery platform can be adapted to send DNA directly into mitochondria, the energy-producing structures within cells.

This initiative is a collaboration with the Medical Research Council Mitochondrial Biology Unit at the University of Cambridge. As reported by labnews.co.uk, the project aims to tackle a significant biological hurdle: the mitochondria are enclosed by a double membrane that naturally blocks the entry of therapeutic DNA, making it one of the most difficult targets in genetic medicine.

Mitochondrial barriers limit current treatments

Most genetic diseases stem from mutations in the cell nucleus, which are easier to target with current gene therapies. However, mutations in mitochondrial DNA cause severe inherited conditions for which few effective treatments exist. The central challenge is not just creating the right genetic material, but getting it across the mitochondrial double membrane to reach the target.

Bitrobius is developing a platform called Gentrafix, which uses plasmid DNA that can replicate within human cells and move to neighboring cells. This approach is designed to reach a larger proportion of affected cells than traditional methods that rely on delivering therapy to individual cells one by one.

Testing novel delivery mechanisms

The new project will investigate if Gentrafix can be modified to use a proprietary DNA-secreting pore to breach the mitochondrial membrane. By combining Bitrobius’s delivery technology with the Cambridge team’s expertise in mitochondrial genetics, the researchers hope to find a reliable way to transport genetic material into these organelles.

Focus remains on technical feasibility

While mitochondrial dysfunction is linked to a wide range of issues, including neurodegenerative diseases, diabetes, and aging, the immediate goal of this grant is not to prove therapeutic efficacy in patients. Instead, the work focuses on the fundamental technical challenge of successful delivery.

If successful, this research could open a route toward genetic medicines for diseases involving mitochondrial DNA. The trade-off is that this is a foundational step; it addresses the delivery mechanism rather than the clinical outcome, meaning significant further research will be required before any treatments can be developed.